Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 4/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.52 |
| ▸ | CDK2 | P24941 | 4/20 | 0.52 |
| ▸ | DBF4 | Q9UBU7 | 4/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | PDCD1 | Q15116 | 10/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 10/20 | 0.40 |
| ▸ | VSIR | Q9H7M9 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.35 |
| ▸ | SLC26A6 | Q9BXS9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12550864 | 0.90 | CDC7 (0.53) | CDC7CCNE1CDK2DBF4GSK3B | |
| SCHEMBL12550860 | 0.87 | CDC7 (0.47) | CDC7CCNE1CDK2DBF4PDCD1 | |
| SCHEMBL1962537 | 0.86 | PIK3CB (0.47) | CDC7CCNE1CDK2DBF4PDCD1 | |
| SCHEMBL1960827 | 0.83 | CDC7 (0.57) | CDC7CCNE1CDK2DBF4GSK3B | |
| SCHEMBL1958965 | 0.71 | CDC7 (0.53) | CDC7CCNE1CDK2DBF4GSK3B | |
| SCHEMBL12506922 | 0.69 | CDC7 (0.56) | CDC7CCNE1CDK2DBF4GSK3B | |
| SCHEMBL1961463 | 0.69 | MAPT (0.40) | CDC7CCNE1CDK2DBF4GSK3B | |
| SCHEMBL1551977 | 0.69 | KDM4E (0.41) | GSK3B | |
| SCHEMBL7946423 | 0.68 | CDC7 (1.00) | CDC7CCNE1CDK2DBF4GSK3B | |
| SCHEMBL12086563 | 0.66 | CDC7 (0.60) | CDC7CCNE1CDK2DBF4GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2313380-B1 | OXADIAZOLE DERIVATIVES FOR TREATING DIABETES | MERCK PATENT GMBH (DE) | 2013-12-11 | — | — | EP | claimed |
| US-8377975-B2 | Oxadiazole derivatives for the treatment of diabetes | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-02-19 | — | — | US | claimed |
| US-8377975-B2 | Oxadiazole derivatives for the treatment of diabetes | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-02-19 | — | — | US | disclosed |
| US-20110139654-A1 | OXADIAZOLE DERIVATIVES FOR THE TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT (DE) | 2011-06-16 | — | — | US | disclosed |
| EP-2313380-A1 | OXADIAZOLE DERIVATIVES FOR TREATING DIABETES | Merck Patent GmbH (DE) | 2011-04-27 | — | — | EP | disclosed |
| WO-2010020305-A1 | OXADIAZOLE DERIVATIVES FOR TREATING DIABETES | MERCK PATENT GMBH (DE) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010020305-A1 | OXADIAZOLE DERIVATIVES FOR TREATING DIABETES | MERCK PATENT GMBH (DE) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110139654-A1 | OXADIAZOLE DERIVATIVES FOR THE TREATMENT OF DIABETES | PFKL, RXFP3, OXA1L | CDC7 967/4885CCNE1 685/4885CDK2 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.